Japanese Wako Pure Chemical Cancer Diagnostics To Reach ¥10 Billion In Five Years
This article was originally published in PharmAsia News
Executive Summary
Japanese diagnostics maker Osaka-based Wako Pure Chemical Industries launched a new micro total analysis system and two testing agents to detect hepatocellular carcinoma. Priced at ¥8 million, the system is able to use smaller dose samples and conduct faster diagnoses in as little as two minutes. The company aims to achieve ¥10 billion in sales after five years. (Click here for more - Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.